Viking Therapeutics (VKTX) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
H.C. Wainwright Assumes Viking Therapeutic (VKTX) at Buy, 'An Underappreciated Microcap'
November 10, 2017 7:17 AM ESTH.C. Wainwright assumes coverage on Viking Therapeutic (NASDAQ: VKTX) with a Buy rating and a price target of $7.00.
Analyst Ed Acre takes over coverage of the name and comments "We view Viking as an underappreciated microcap stock with five novel drugs in the... More
